Aurobindo Pharma gets OAI status from US FDA for Eugia Pharma's Bhiwadi Unit

Aurobindo Pharma gets OAI status from US FDA for Eugia Pharma's Bhiwadi Unit


Aurobindo Pharma announced that the United States Food and Drug Administration (US FDA) has concluded an inspection at its subsidiary, Eugia Pharma’s Bhiwadi facility, classifying it as Official Action Indicated (OAI).

According to an exchange filing, the US FDA conducted an inspection at Unit-II of Eugia Pharma Specialities, a wholly owned subsidiary of the company, located in the RIICO Industrial Area, Phase III, Bhiwadi, Rajasthan, between 3 November and 14 November 2025. At the conclusion of the inspection, a Form 483 with nine observations was issued.

The US FDA has now determined the inspection classification status of the unit as official action indicated (OAI).

 

The company said, ‘At this point in time, the company doesnt foresee any impact on the business.’ The company is committed to maintaining the highest quality manufacturing standards at all of its facilities across the globe.

Aurobindo Pharma is principally engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services.

The companys consolidated net profit rose 7.6% to Rs 910.29 crore on a 9% increase in net sales to Rs 8,604.51 crore in Q3 FY26 over Q3 FY25.

Shares of Aurobindo Pharma shed 0.54% to Rs 1,280.50 on the BSE.

Powered by Capital Market – Live News



Source link

FPI flows to remain volatile; outlook hinges on West Asia easing: Antique

FPI flows to remain volatile; outlook hinges on West Asia easing: Antique



Foreign portfolio investor (FPI) flows into Indian equities have turned negative again in March so far and are likely to remain volatile in the near term due to heightened geopolitical tensions in West Asia, according to analysts at Antique Stock Broking. 


The brokerage expects flows to normalise once tensions ease, supported by relatively reasonable valuations versus developed markets, a likely recovery in corporate earnings over financial years 2026 to 2028 (FY26-28) on a low base, strong macro-economic fundamentals, and low FPI ownership in India. 


So far this year, global funds have sold Indian equities worth ₹86,285 crore, according to NSDL data. In calendar year 2025, total FPI outflows stood at over ₹1.66 trillion. In 2026 so far, FPIs sold shares worth ₹35,962 crore in January, but turned net buyers in February with inflows of ₹22,615 crore, the highest monthly buying since September 2024. 

 


Antique noted that both mutual funds and FPIs continue to hold a negative stance on investment-linked sectors such as capital goods, power utilities and cement, while maintaining an overweight or less underweight position on consumer-linked sectors including automobiles, consumer durables and fast-moving consumer goods. The negative stance on financials has moderated in recent months. 


The report highlighted divergent positioning between mutual funds and FPIs in sectors such as chemicals, consumer services, information technology services and telecom. 

In February, mutual funds increased exposure to consumer services, information technology (IT) services, cement and telecom, while reducing positions in metals and mining, power, automobiles and oil and gas. In contrast, FPIs were relatively more active buyers in capital goods, metals and power, while they sharply reduced exposure to information technology services, Antique Stock Broking said. 
READ | Microcaps in value zone, but West Asia war may delay recovery: Samco Sec 
Further, foreign brokerages have started to cut their year-end targets for the Nifty 50 index amid the ongoing West Asia conflict. Nomura now sees the Nifty 50 index at 24,900 levels, down 15 per cent versus its earlier target of 29,300.  Citi Research, too, have cut their 2026-end Nifty target by 5.2 per cent to 27,000.  


Through this phase of market correction, Nomura expects coal, oil producers, healthcare, pharma, staples, and telecom sectors to outperform. While the research and brokerage house remains constructive on these sectors, it finds valuations demanding in the healthcare and staples spaces. 


========== 


(Disclaimer: The views and investment tips expressed by the analysts in this article are their own and not those of the website or its management. Business Standard advises users to check with certified experts before taking any investment decisions.)



Source link

Nifty Microcap Outlook: Microcaps in value zone, but West Asia war may delay recovery: Samco Sec

Nifty Microcap Outlook: Microcaps in value zone, but West Asia war may delay recovery: Samco Sec


The given chart of P/B-wise market breadth for the Nifty Microcap 250 highlights a consistent relationship between valuation dispersion and index turning points. The data suggests that extreme compression in P/B multiples often precedes price stabilisation and eventual recovery. 


A key observation is that whenever more than 75 per cent of stocks trade below a P/B multiple of 6, the index tends to be near a cyclical bottom. While this signal does not indicate an immediate reversal, it has historically acted as a high-probability zone for accumulation, where downside risk begins to be limited and smart money gradually builds positions.

 
 


In addition, a sharper near-term trigger emerges when over 30 per cent of stocks fall below a P/B of 2. This reflects deep value conditions across the broader market and has often been followed by short-term upside momentum. Notably, a similar setup was seen in the period before June 2023, when the index went through a consolidation phase with such percentage of stocks with PBV below 2 were above 30 per cent before delivering a strong rally.

 


At present, this metric stands at 31 per cent, placing the market in a zone where the probability of a tactical bounce is rising. However, external variables remain critical. Ongoing geopolitical tensions, particularly in the West Asia, could delay or dilute the pace of recovery.

 


From a strategy perspective, this PB breadth indicator serves as a useful contrarian tool. It helps identify phases of market stress where valuations become attractive on a broad basis. Investors can use this signal to track bottom formation and prepare for potential upside, rather than attempting to time exact reversals.

 


Overall, the setup indicates early signs of value emergence, with improving risk-reward in the microcap space.

 


(Disclaimer: This article is by Raj Gaikar, research analyst, Samco Securities. Views expressed are his own.)



Source link

Market mood hits 6-month low in March, says BofA fund manager survey

Market mood hits 6-month low in March, says BofA fund manager survey



The “frothy bull” market sentiment of the past few months is ending as global investors turn bearish, according to Bank of America’s latest fund manager survey. The bank’s broadest measure of the market’s mood fell to a six-month low in March and cash levels surged, strategist Michael Hartnett wrote in a note. 


Participants cited the ongoing war in Iran and turmoil in private credit as reasons to be nervous. The survey showed the biggest jump in cash since March 2020, with holdings reaching 4.3 per cent in March. For the eighth month in a row, respondents said that private equity and private credit are the most likely source of a “systemic credit event.” 

 


The war in the West Asia has turned investor attention away from the AI race, which was the focus of last month’s survey, to the risks facing the global economy as oil prices flirt with $100 a barrel. At the same time, market jitters around banks’ exposure to private credit are increasing. Still, investors aren’t yet as bearish as they were during April’s tariff turmoil. Positioning is “far from uber-bear levels seen at recent big lows,” Hartnett said.

First Published: Mar 17 2026 | 11:01 PM IST



Source link

Aurobindo Pharma gets OAI status from US FDA for Eugia Pharma's Bhiwadi Unit

Mafatlal Industries receives order worth Rs 114 cr


From Odisha Computer Application Centre

Mafatlal Industries has received an order valued at approximately Rs 114 crore from the Odisha Computer Application Centre (OCAC).

The order pertains to the setting up of 500 robotic laboratories across 16 districts in the State of Odisha under the School and Mass Education Department. The project is scheduled to be executed over a period of five years.

Powered by Capital Market – Live News

 

Disclaimer: No Business Standard Journalist was involved in creation of this content

First Published: Mar 17 2026 | 8:04 PM IST



Source link

Aurobindo Pharma gets OAI status from US FDA for Eugia Pharma's Bhiwadi Unit

Ceigall subsidiary secures two projects of Punjab Infrastructure Development Board


Ceigall Infra Projects (CIPPL), a wholly owned subsidiary of Ceigall India (CIL) has emerged as the L1 bidder in the financial bid opening for two (2) tenders by the Punjab Infrastructure Development Board on 16 March 2026. These include:

– Construction And Development of the World Class Urban Street in Ludhiana On Hybrid Annuity Model Package 1 (Bid cost of Rs 108 crore).

– Construction And Development of the World Class Urban Street in Ludhiana On Hybrid Annuity Model Package 3 (Bid cost of Rs 99 crore).

Powered by Capital Market – Live News

 

Disclaimer: No Business Standard Journalist was involved in creation of this content

First Published: Mar 17 2026 | 7:50 PM IST



Source link

YouTube
Instagram
WhatsApp